Liquid biopsy is transforming cancer detection through minimally invasive genomic testing, offering new opportunities for earlier diagnosis and monitoring.
Precision medicine in oncology is no longer a distant vision- it is a critical necessity. As cancer care evolves, biomarker-driven diagnostics, genomic sequencing, digital pathology, and AI-powered insights are transforming how clinicians detect.
Tumor genomic profiling helps identify actionable mutations to guide targeted therapies and clinical decisions. Understanding when to use it is key to maximizing its impact in precision oncology.
Cancer has long been recognized as a biologically heterogeneous disease, yet historically it has often been treated using relatively uniform therapeutic approaches.

A multidisciplinary community committed to advancing research, education, and clinical standards in precision medicine.
Copyright 2026. American Board of Precision Medicine. All Rights Reserved.